Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine

Pharmacology Biochemistry and Behavior

Volumn 101, Issue 2, 2012, Pages 307-310

  Busanello, Alcindo ^a   Peroza, Luis R ^a   Wagner, Caroline ^a   Sudati, Jéssie H ^a   Pereira, Romaiana P ^a   Prestes, Alessandro De S ^a   Rocha, João B T ^a   Fachinetto, Roselei ^a   Barbosa, Nilda B V ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Exploratory activity; Locomotor activity; Neurodegenerative disease; Open field test; Orofacial dyskinesia; Tardive dyskinesia

Indexed keywords

FLUPHENAZINE ENANTHATE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; LOCOMOTION; MALE; MASTICATION; NEUROPROTECTION; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT;

ANIMALIA; RATTUS; VITACEAE;

EID: 84984568111     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.01.007     Document Type: Article

References (47)

1. V.C. Abílio, R.H. Silva, R.C. Carvalho, C. Grassl, M.B. Calzavara, and S. Registro Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia Neuropharmacology 47 2004 263 272 (Pubitemid 38824650)
2. O.A. Andreassen, and H.A. Jorgensen Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61 2000 525 541 (Pubitemid 30169057)
3. O.A. Andreassen, R.J. Ferrante, T.O. Aamo, M.F. Beal, and H.A. Jorgensen Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats Neuroscience 122 2003 717 725 (Pubitemid 37410293)
4. T.S. Anekonda Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52 2006 316 326 (Pubitemid 44291807)
5. P.L. Broadhurst Experiments in psychogenetics H.J. Eysenk, Experiments in personality 1960 Routledge & Kegan Paul London 76
6. L. Brown, P.A. Kroon, D.K. Das, S. Das, A. Tosaki, and V. Chan The biological responses to resveratrol and other polyphenols from alcoholic beverages Alcohol Clin Exp Res 33 2009 1513 1523
7. M.E. Burger, R. Fachinetto, L. Calegari, M.W. Paixão, A.L. Braga, and J.B.T. Rocha Effects on age on orofacial dyskinesia reserpine-induced and possible protection of diphenyl-diselenide Brain Res Bull 64 2004 339 345 (Pubitemid 39550770)
8. M.E. Burger, R. Fachinetto, G. Zeni, and J.B.T. Rocha Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain Pharmacol Biochem Behav 81 2005 608 615 (Pubitemid 40966809)
9. M.E. Burger, R. Fachinetto, A. Alves, L. Calegari, and J.B.T. Rocha Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats Brain Res 1031 2005 202 210 (Pubitemid 40103531)
10. A. Busanello, N.B. Barbosa, L.R. Peroza, L.E. Farias, M.E. Burger, and K.P. Barreto Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice Behav Pharmacol 22 2011 71 75
11. J.L. Cadet, J.B. Lohr, and D.V. Jeste Free radical and tardive dyskinesia Trends Neurosci 9 1986 107 108
12. J.L. Cadet, J.B. Lohr, and D.V. Jeste Tardive dyskinesia and Schizophrenic burnout: the possible involvement of cytotoxic free radicals F.A. Henn, L.E. DeLisi, Handbook of schizophrenia: the neurochemistry and pharmacology of schizophrenia 1987 Elsevier Amsterdam 425 438
13. V. Calabrese, C. Cornelius, C. Mancuso, G. Pennisi, S. Calafato, and F. Bellia Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity Neurochem Res 33 2008 2444 2471
14. D.E. Casey Tardive dyskinesia: reversible and irreversible Psychopharmacology 2 1985 88 97
15. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.L. Beaudeux Resveratrol bioavailability and toxicity in humans Mol Nutr Food Res 54 2010 7 16
16. G.E. Crane Persistent dyskinesia Br J Psychiatry 122 1973 395 405
17. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
18. Di Liberto V, Mäkelä J, Korhonen L, Olivieri M, Tselykh T, Mälkiä A, et al. Involvement of estrogen receptors in the resveratrol-mediated increase in dopamine transporter in human dopaminergic neurons and in striatum of female mice. Neuropharmacology 2012;62:1011-8.
19. M. Ebadi, and S.K. Srinivasan Pathogenesis, prevention and treatment of neuroleptic-induced movement disorders Pharmacol Rev 47 1995 575 604 (Pubitemid 26006142)
20. R. Fachinetto, M.B. Burger, C. Wagner, D.C. Wondracek, V.B. Brito, and C.W. Nogueira High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats Pharmacol Biochem Behav 81 2005 585 592 (Pubitemid 40966806)
21. R. Fachinetto, J.G. Villarinho, C. Wagner, R.P. Pereira, R.L. Puntel, and M.W. Paixão Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats Psychopharmacology 194 2007 423 432 (Pubitemid 47389341)
22. R. Fachinetto, J.G. Villarinho, C. Wagner, R.P. Pereira, D.S. Ávila, and M.E. Burger Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter Prog Neuropsychopharmacol Biol Psychiatry 31 2007 1478 1486 (Pubitemid 47302567)
23. R.R. Faria, V.C. Abilio, C. Grassl, C.C. Chinen, L.T. Negrao, and J.P. de Castro Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity Neuropharmacology 48 2005 993 1001 (Pubitemid 40602607)
24. +-induced cytotoxicity in neuronal PC12 cells J Neurosci Res 70 2002 90 96
25. L. Gunne, J. Häggström, and B. Sjöquist Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis Nature 309 1984 347 349 (Pubitemid 14145835)
26. E.D. Hall, R.A. Vaishnav, and A.G. Mustafá Antioxidant therapies for traumatic brain injury Neurotherapeutics 7 2010 51 61
27. L. Ho, L.H. Chen, J. Wang, W. Zhao, S.T. Talcott, and K. Ono Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration J Alzheimers Dis 16 2009 59 72
28. D.V. Jeste, S.G. Potkin, S. Sinhá, S. Feder, and R.J. Wyatt Tardive dyskinesia-reversible and persistent Arch Gen Psychiatry 36 1979 585 590
29. J.M. Kane Tardive dyskinesia: epidemiology and clinical presentation F.E. Bloom, D.J. Kupfer, Psychopharmacology: the fourth generation of progress vol. 39 1995 Raven Press New York 1485 1495
30. J.M. Kane, and J.M. Smith Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 Arch Gen Psychiatry 39 1982 473 481 (Pubitemid 12152816)
31. S. Lee, D. Oh, S. Jung, Y. Kim, H. Cho, and J. Koh Neuroleptic drugs alter the dopamine transporter-mediated uptake and release of dopamine: a possible mechanism for drug-induced tardive dyskinesia Pharmacol Res 35 1997 446 450
32. M.K. Lee, S.J. Kang, M. Poncz, K.J. Song, and K.S. Park Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine Exp Mol Med 39 2007 376 384 (Pubitemid 47037629)
33. J.B. Lohr, J.L. Cadet, M.A. Lohr, D.V. Jeste, and R.J. Wyatt Alpha-tocopherol in tardive dyskinesia Lancet 1 1987 913 934
34. J.B. Lohr, R. Kuczenski, and A.B. Niculescu Oxidative mechanisms and tardive dyskinesia CNS Drugs 17 2003 47 62 (Pubitemid 36044348)
35. P.S. Naidu, A. Singh, P. Kaur, and S.K. Kulkarni Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia Neuropharmacology 44 2003 1100 1106 (Pubitemid 36570433)
36. M. Okawara, H. Katsuki, E. Kurimoto, H. Shibata, T. Kume, and A. Akaike Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults Biochem Pharmacol 73 2007 550 560 (Pubitemid 46038859)
37. Pereira RP, Fachinetto R, de Souza Prestes A, Wagner C, Sudati JH, Boligon AA, et al. Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats. J Neural Transm 2011;96:324-32.
38. A. Post, M. Rucker, F. Ohl, M. Uhr, F. Holsboer, and O.F.X. Almeida Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity Neuropsychopharmacology 26 2002 397 407 (Pubitemid 34159217)
39. J.P. Redrobe, M. Bourin, M.C. Colombel, and G.B. Baker Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity Psychopharmacology (Berl) 138 1998 1 8 (Pubitemid 28319041)
40. O. Sadan, M. Bahat-Stromza, Y. Gilgun-Sherki, D. Atlas, E. Melamed, and D. Offen A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia Clin Neuropharmacol 28 2005 285 288 (Pubitemid 44378620)
41. 1 binding site correlates of haloperidol-induced oral dyskinesias in rat Exp Neurol 127 1994 62 69
42. G.J. Soleas, M. Angelini, L. Grass, E.P. Diamandis, and D.M. Goldberg Absorption of transresveratrol in rats Methods Enzymol 335 2001 145 154
43. 1A receptor function in a rodent model of tardive dyskinesia Neuroscience 101 2000 629 635
44. V. Vingtdeux, U. Dreses-Werringloer, H. Zhao, P. Davies, and P. Marambaud Therapeutic potential of resveratrol in Alzheimer's disease BMC Neurosci 3 2008 2:S6
45. Q. Wang, J. Xu, G.E. Rottinghaus, A. Simonyi, D. Lubahn, and G.Y. Sun Resveratrol protects against global cerebral ischemic injury in gerbils Brain Res 958 2002 439 447 (Pubitemid 35441199)
46. M.G. Woerner, J.M. Kane, J.A. Lieberman, J. Alvir, K.J. Bergmann, and M. Borenstein The prevalence of tardive dyskinesia J Clin Psychopharmacol 11 1991 34 42
47. M. Yáñez, N. Fraiz, E. Cano, and F. Orallo Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity Biochem Biophys Res Commun 344 2006 688 695